This article is more than 5 years old. Information may no longer be current.
LUNAR study: Latanoprostene bunod non-inferior to timolol over 3 months
Click Here to Manage Email Alerts
Latanoprostene bunod was shown to be non-inferior to timolol in treating patients with open-angle glaucoma or ocular hypertension, according to results of the LUNAR study.
In addition, latanoprostene bunod reduced IOP significantly more than timolol at all but the earliest time points evaluated.
The prospective, randomized, double-masked clinical trial included 387 patients; 259 patients were randomized to receive latanoprostene bunod 0.024% instilled once daily in the evening and 128 patients were randomized to receive timolol 0.5% instilled twice daily for 3 months.
Mean baseline diurnal IOP was 26.6 mm Hg in the latanoprostene bunod group and 26.4 mm Hg in the timolol group.
IOP was evaluated at 2 weeks, 6 weeks and 3 months at 8 a.m., 12 p.m. and 4 p.m. at each visit.
Mean IOP reduction with latanoprostene bunod was non-inferior to timolol and significantly greater (P .025) at all time points except the first (8 a.m. on week 2).
IOP was reduced by 25% or more from baseline in 31% of patients in the latanoprostene bunod group and 18.5% of patients in the timolol group; the between-group difference was statistically significant (P = .007).
IOP was reduced to 18 mm Hg or less in 17.7% of patients in the latanoprostene bunod group and 11.1% of patients in the timolol group over all time points and visits.
Treatment-emergent ocular adverse events were more common in the latanoprostene bunod group than in the timolol group. All events were mild to moderate, except for one case of severe hyperemia. – by Matt Hasson
Disclosure: Medeiros reports he has received institutional grant money from NEI, Allergan, Alcon and Bausch + Lomb and has served as a paid consultant for Allergan, Alcon, Reichert, Carl Zeiss Meditec and Heidelberg Engineering. See the study for a full list of all other authors’ relevant financial disclosures.
Collapse
Medeiros F, et al. Am J Ophthalmol. 2016;doi:1016/j.ajo.2016.05.012.
Click Here to Manage Email Alerts